Image source: Shutterstock
Highlights
Net profit after tax rose 43% to NZ$377.2 million in FY2025.
Operating revenue increased 16% to NZ$2.02 billion.
FY2026 net profit forecasted between NZ$390 million and NZ$440 million.
Health equipment manufacturer Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) announced a 43% increase in net profit after tax for the 2025 financial year, reaching NZ$377.2 million (US$348.1 million). The company attributed the surge to demand in its hospital consumables segment and masks used in the treatment of obstructive sleep apnea.
Total operating revenue for the year reached NZ$2.02 billion, marking a 16% increase compared to the previous financial year. The company declared a final dividend of 42.5 cents per share, reflecting a 2% rise year over year.
In a statement accompanying the financial results, Fisher & Paykel indicated positive performance across its core business areas. The hospital product group and obstructive sleep apnea mask sales were highlighted as key contributors to the company’s overall financial uplift during FY2025.
Looking ahead, the company provided guidance for the 2026 financial year, forecasting operating revenue to be between NZ$2.15 billion and NZ$2.25 billion. Net profit after tax is expected to range between NZ$390 million and NZ$440 million. The company anticipates an improvement in gross margin during FY2026, despite external cost pressures.
As part of its forward-looking commentary, Fisher & Paykel noted an expected 50-basis point impact on gross margin due to United States tariffs on hospital products sourced from New Zealand. The company said that this factor has been included in its financial outlook.
Managing Director and Chief Executive Officer Lewis Gradon stated that the company's strategic approach remains focused on maintaining operational efficiency in light of trade policy changes. “Our action in response to any trade policy developments will be driven by our longstanding approach, which is to mitigate cost increases from any source by identifying and implementing continuous improvements and efficiency gains across all of our business processes,” Gradon said.
Fisher & Paykel Healthcare is one of New Zealand’s leading medical device companies, with products used in over 120 countries. The firm designs, manufactures, and markets equipment and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnea.






Please wait processing your request...